Clinical studies

/sg/inflammation/nintedanib/about-pulmonary-fibrosis/ra-ild-delphi-consensus-screening-algorithm

A1-R101||A2-R101||RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/how-identify-patients-ra-ild-who-can-benefit-ofev

A1-R101||A2-R101||How to identify patients with RA-ILD who can benefit from OFEV
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/empa-kidneys-further-results-on-annual-rate-of-change-in-egfr

EK22||EMPA-KIDNEY's Further Results on Annual Rate of Change in eGFR
/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-ppf-diagnosis-and-treatment-atsersjrsalat-guideline

FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/how-recognize-ild-ppf-patients-ctd

FSIN||How to recognize ILD in PPF patients with CTD
/sg/inflammation/nintedanib/efficacy/inbuild-trial-efficacy-autoimmune-ild-patients

SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients)
/sg/inflammation/nintedanib/efficacy/inbuild-trial-population-and-baseline-medications

SGOFV2023COM||INBUILD® Trial Population and Baseline Medications
/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-focus-autoimmune-ilds

Progressive Pulmonary Fibrosis: focus on autoimmune ILDs
/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-diagnosis-treatment-atsersjrsalat-guideline

Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/importance-prompt-treatment-ipf

The Importance of Prompt Treatment of IPF
/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-gioswing-sequential-cohort-combined-analysis

SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)
/sg/inflammation/nintedanib/efficacy/key-managing-progression-ssc-ild-patients

SGOFV2022COM||The key to managing progression in SSc-ILD patients
/sg/oncology/giotrif/sequencing/totality-outcome-of-afatinib-giotrif-sequential-treatment-in-patients-with-egfrm-nsclc

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC
/sg/metabolic/glyxambi/tool-apps/for-your-practice/benefits-early-intensification

1 Benefits of Early Intensification
/sg/metabolic/glyxambi/tool-apps/for-your-practice/2-proven-diabetic-medications

2 Proven Diabetic Medications
/sg/metabolic/glyxambi/tool-apps/for-your-practice/3-convincing-cvots

3 Convincing CVOTs
/sg/respiratory/ofev/about-pulmonary-fibrosis/ra-ild-patient-profile-julie

A1-R101||A2-R101||RA-ILD Patient Profile - Julie
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/ssc-ild-patient-profile-stephanie

A1-R101||A2-R101||SSc-ILD Patient Profile - Stephanie
/sg/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-drvsmith

A2-R101||Rheum MTE – Management Strategies Key highlights -Dr. V. Smith
/sg/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-dr-oliver-distler

A2-R101||Rheum MTE – Management Strategies Key highlights -Dr. Oliver Distler
/sg/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-dr-anna-maria-hoffmann-vold

A2-R101||Rheum MTE – Management Strategies Key highlights - Dr. Anna Maria Hoffmann-Vold
/sg/inflammation/nintedanib/efficacy/why-should-ssc-ild-patients-be-treated-early

Why should SSc-ILD patients be treated early?
/sg/oncology/giotrif/efficacy/south-korean-dataset-frontline-giotrif-uncommon-egfr-mutations

South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
/sg/inflammation/nintedanib/efficacy/acute-exacerbations-ilds-and-role-ofev

Acute Exacerbations of ILDs and the Role of OFEV®
/sg/metabolic/empagliflozin/tools-apps/2022-ada-standard-care

2022 ADA Standard of Care
/sg/oncology/giotrif/sequencing/totality-outcome-afatinib-giotrif-sequential-treatment-patients-egfrm-nsclc

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort)
/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-upswing-sequential-cohort

SEREAL||GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
/sg/oncology/giotrif/efficacy/giotrif-safety-and-effectiveness-real-world

SEREAL||GIOTRIF® safety and effectiveness in the real world
/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-japan

SEREAL||Real-world evidence: GIOTRIF® in Japan
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-droliver-distler

Meet-the-Expert with Dr. Oliver Distler: Highlights Report
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-dramhoffmann-vold

Meet-the-Expert with Dr. Hoffmann-Vold: Highlights Report
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-drvsmith

Meet-the-Expert with Dr. Vanessa Smith: Highlights Report
/sg/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-drmaringer

Meet-the-Expert with Dr. Martin Aringer: Highlights Report
/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-taiwan

Real-world evidence: GIOTRIF® in Taiwan
/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-south-korea-reset-study

GIOTRIF® followed by 3rd generation TKI in RESET study
/sg/metabolic/empagliflozin/tools-apps/stay-connected-patient-material

Stay Connected Patient Material
/sg/metabolic/empagliflozin/tools-apps/jardiance-patient-initiation-guide

JARDIANCE Patient Initiation Guide
/sg/cardiovascular/dabigatran-etexilate/patient-materials/patient-alert-card

Patient Alert Card
/sg/oncology/giotrif/efficacy/giotrif-efficacy-and-safety-elderly-egfrm-nsclc-patients

GIOTRIF® in elderly
/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-efficacy-taiwan-and-korea

GIOTRIF® RWE in uncommon EGFR mutations
/sg/oncology/giotrif/efficacy/pre-clinical-and-clinical-activity-giotrif-uncommon-egfr-mutations

GIOTRIF® in uncommon EGFR mutations
/sg/oncology/giotrif/efficacy/south-korea-real-world-data

GIOTRIF® RWE in South Korea
/sg/oncology/giotrif/dosing-and-administration/giotrif-maintains-efficacy-despite-dose-modification

GIOTRIF® maintains efficacy despite dose modification
/sg/oncology/giotrif/safety/ae-management-focus-paronychia

AE management in focus: Paronychia
/sg/oncology/giotrif/safety/ae-management-focus-skin-rash

AE management in focus: Skin Rash
/sg/oncology/giotrif/efficacy/sequential-treatment-afatinib-and-osimertinib-patients-egfr-mutation-positive-non-small

Publication: GioTag
/sg/oncology/giotrif/efficacy/real-world-retrospective-study-suggests-giotrif-viable-2nd-line-treatment-option

GIOTRIF® in SqCC
/sg/metabolic/empagliflozin/tools-apps/metabolism-jardiance-esc-easd-guideline-infographic

Metabolism Jardiance- ESC-EASD Guideline Infographic
/sg/metabolic/empagliflozin/prescribing-information/empagliflozin-metfromin-hcl-jardiance-duo-prescribing-information

Empagliflozin + Metfromin HCl (Jardiance Duo®) Prescribing Information
/sg/metabolic/empagliflozin/prescribing-information/empagliflozin-jardiance-prescribing-information

Empagliflozin (Jardiance®) Prescribing Information
/sg/oncology/giotrif/efficacy/giotrif-delays-median-time-cns-progression-versus-chemotherapy

SEREAL||Impact of GIOTRIF® in delaying CNS progression
/sg/oncology/giotrif/safety/management-giotrif-adverse-events-real-world

SEREAL||Management of GIOTRIF® adverse events in the real world
/sg/oncology/giotrif/efficacy/giotrif-treatment-nsclc-harbouring-uncommon-egfr-mutations-published-pooled-analysis-693

SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients
/sg/oncology/giotrif/efficacy/giotrif-real-world-data-patientss-cns-involvement

SEREAL||GIOTRIF® RWE in patients with brain metastases
/sg/oncology/giotrif/efficacy/taiwan-real-world-data

SEREAL||GIOTRIF® RWE in Taiwan
/sg/oncology/giotrif/efficacy/consistent-efficacy-giotri-observed-across-real-world-studies

SEREAL||GIOTRIF® efficacy in the real-world
/sg/oncology/giotrif/efficacy/giotrif-significantly-reduces-relative-risk-disease-progression-or-death-vs-gefitinib

SEREAL||GIOTRIF® in LUX-Lung 7
/sg/oncology/giotrif/efficacy/giotrif-potency-and-specificity-against-egfr-mutations

GIOTRIF® in common EGFR mutations
/sg/oncology/giotrif/dosing-and-administration/results-realgido-global-real-world-study

SEREAL||RealGiDo: Impact of GIOTRIF® dose adjustment in the real-world setting
/sg/oncology/giotrif/japan-real-world-evidence-supports-sequential-treatment-use-upfront-2nd-generation-tki

SEREAL||GIOTRIF® sequential RWE in Japan
/sg/oncology/giotrif/giotag-1st-global-study-show-feasibility-sequential-therapy-giotrif-followed-osimertinib

SEREAL||GioTag sequence may delay time to chemotherapy
/sg/oncology/giotrif/post-hoc-analyses-lux-lung-trials-giotrifr-followed-3rd-generation-tki

SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Impact on OS)
/sg/oncology/giotrif/uptake-subsequent-therapy-lux-lung-3-6-and-7

SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Uptake rate)
/sg/oncology/giotrif/efficacy/first-line-giotrif-data-over-30-real-world-studies-date

GIOTRIF® real world experience in Asia
/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/5-years-empa-reg-outcome-journey

5 years EMPA-REG OUTCOME Journey
/sg/inflammation/nintedanib/prescribing-information/nintedanib-ofev-prescribing-information

Nintedanib (Ofev®) Prescribing Information
/sg/inflammation/nintedanib/efficacy/largest-prospective-phase-iii-clinical-trial-patients-ssc-ild

SGOFV2023COM||SENSCIS® trial
/sg/inflammation/nintedanib/efficacy/exploratory-analysis-suggests-ofev-may-extend-life-expectancy

Mortality data in IPF
/sg/inflammation/nintedanib/efficacy/ofev-slows-fvc-decline-regardless-baseline-fvc-impairment

OFEV® in IPF patients with FVC ≤50% predicted
/sg/inflammation/nintedanib/efficacy/ofev-significantly-reduces-risk-ae-ipf-pooled-inpulsis-1-and-2

OFEV® and acute IPF exacerbations
/sg/inflammation/nintedanib/efficacy/consistent-treatment-effect-ofev-irrespective-disease-stage

OFEV® across different disease severities
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/vigilance-and-proactivity-are-critical-reducing

SGOFV2023COM||Screening for ILD in your SSc patients
/sg/inflammation/nintedanib/safety/management-ofev-related-diarrhoea

Managing your IPF patients on OFEV®
/sg/inflammation/nintedanib/safety/most-common-gi-related-adverse-events-ofevr-are-mild-moderate

SGOFV2023COM||Managing your SSc-ILD patients on OFEV®
/sg/inflammation/nintedanib/dosage/offer-your-patients-one-capsule-twice-daily

Dosing simplicity with OFEV®
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/regular-screening-critical-ild-can-develop-early

SGOFV2023COM||ILD is the leading cause of mortality in SSc
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/once-lung-function-lost-ipf-it-lost-forever

Lung function decline
/sg/inflammation/nintedanib/about-pulmonary-fibrosis/learn-how-acute-exacerbation-ipf-can-impact

Risk of acute exacerbations
/sg/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-praxbind

Prescribing Information for Praxbind®
/sg/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-pradaxa

Prescribing Information for Pradaxa®
/sg/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive

Publication: GioTag Final Analysis
/sg/metabolic/empagliflozin/cv-risk-protection/emprise®-new-data-release-ada-congress-2020

EMPRISE® New Data Release in ADA Congress 2020
/sg/oncology/giotrif/efficacy/giotrif-delays-onset-risk-cns-progression

GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases
/sg/oncology/giotrif/efficacy/giotrif-vs-gefitinib-1st-line-treatment-egfrm-nsclc

GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
/sg/oncology/giotrif/efficacy/giotrif-provides-3-years-long-term-response

GIOTRIF® provides ≥3 years long-term response even with dose modification
/sg/oncology/giotrif/safety/xerosis-management

AE management in focus: Xerosis
/sg/oncology/giotrif/safety/stomatitis-management

AE management in focus: Stomatitis
/sg/oncology/giotrif/safety/scalp-lesion-management

AE management in focus: Scalp lesion
/sg/oncology/giotrif/safety/strategies-optimise-management-egfr-tki-related-side-effects

Strategies to optimise the management of EGFR  TKI-related side effects
/sg/oncology/giotrif/safety/ae-management-focus-diarrhoea

AE management in focus: Diarrhoea
/sg/metabolic/empagliflozin/cv-risk-protection/emprise-empagliflozin-real-world-effectiveness

EMPRISE - Empagliflozin Real World Effectiveness
/sg/metabolic/linagliptin/prescribing-information/trajenta-duo-prescribing-information

Linagliptin + Metformin HCl (Trajenta Duo®) Prescribing Information
/sg/metabolic/linagliptin/prescribing-information/trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information
/sg/oncology/giotrif/sequencing/sequential-treatment-afatinib

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study
/sg/respiratory/spiolto/tovito/tovito-phase-iii-clinical-trial-programme

TOVITO® Clinical Trial Programme
/sg/respiratory/spiolto/prescribing-information

Spiolto® Respimat® Prescribing Information
/sg/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information
Load more